Inhibiting CK2 in breast cancer: From molecular targets to drug candidates

Key Points

• CK2 inhibition contributes to reducing breast cancer cell proliferation, enhancing treatment efficacy.
• Observed a significant reduction in tumor growth by up to 40% when targeting CK2 in specific models.
• Assessment of multiple molecular targets led to promising drug candidates, demonstrating effective inhibition of CK2 activity.
• Highlights the need for developing CK2 inhibitors as potential breast cancer therapies, suggesting further preclinical studies are essential.